Elena S. Fedenko

Elena S. Fedenko

Auto-generated profile, based on publicly available information

Elena S. Fedenko

National Research Center — Institute of Immunology Federal Medical-Biological Agency

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2010 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
KRK. Reginald
K. Reginald
KWK. Westritschnig
K. Westritschnig
TWT. Werfel
T. Werfel
AHA. Heratizadeh
A. Heratizadeh
NNN. Novak
N. Novak
RVRudolf Valenta
Rudolf Valenta

18 February 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
KNKatarzyna Niespodziana
Katarzyna Niespodziana
KBKristina Borochova
Kristina Borochova
PPPetra Pazderova
Petra Pazderova
TSThomas Schlederer
Thomas Schlederer
NANatalia Astafyeva
Natalia Astafyeva
RVRudolf Valenta
Rudolf Valenta
Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma.

1 April 2011 in Self/Nonself
Verified
Journal Article
Open access
EFElena S. Fedenko
Elena S. Fedenko
OEOlga Elisyutina
Olga Elisyutina
TFTatiana M. Filimonova
Tatiana M. Filimonova
MBMargarita N. Boldyreva
Margarita N. Boldyreva
OBO. V. Burmenskaya
O. V. Burmenskaya
RKRakhim M. Khaitov
Rakhim M. Khaitov
OBJECTIVES: Atopic dermatitis (AD) is an increasingly common, chronic, relapsing, inflammatory skin disease characterized by impaired epidermal barrier function and cutaneous inflammation. The prev...

13 September 2023 in Allergy
Verified
Journal Article
Open access
GBGeorgii Brazhnikov
Georgii Brazhnikov
ESEvgenii Smolnikov
Evgenii Smolnikov
ALAlla Litovkina
Alla Litovkina
TJTianchi Jiang
Tianchi Jiang
ASArtem Shatilov
Artem Shatilov
RCRaffaela A. Campana
Raffaela A. Campana
Background: The nature of epitopes on Bet v 1 recognized by natural IgG antibodies of birch pollen allergic patients and birch pollen‐exposed but non‐sensitized subjects has not been studied in detail.Objective: To investigate IgE and IgG recognition of Bet v 1 and to study the effects of natural Bet v 1‐specific IgG antibodies on IgE recognition of Bet v 1 and Bet v 1‐induced basophil activation.Methods: Sera from birch pollen allergic patients (BPA, n = 76), allergic patients without birch pollen allergy (NBPA, n = 40) and non‐allergic individuals (NA, n = 48) were tested for IgE, IgG as well as IgG1 and IgG4 reactivity to folded recombinant Bet v 1, two unfolded recombinant Bet v 1 fragments comprising the N‐terminal (F1) and C‐terminal half of Bet v 1 (F2) and unfolded peptides spanning the corresponding sequences of Bet v 1 and the apple allergen Mal d 1 by ELISA or micro‐array analysis. The ability of Bet v 1‐specific serum antibodies from non‐allergic subjects to inhibit allergic patients IgE or IgG binding to rBet v 1 or to unfolded Bet v 1‐derivatives was assessed by competition ELISAs. Furthermore, the ability of serum antibodies from allergic and non‐allergic subjects to modulate Bet v 1‐induced basophil activation was investigated using rat basophilic leukaemia cells expressing the human FcεRI which had been loaded with IgE from BPA patients.Results: IgE antibodies from BPA patients react almost exclusively with conformational epitopes whereas IgG, IgG1 and IgG4 antibodies from BPA, NBPA and NA subjects recognize mainly unfolded and sequential epitopes. IgG competition studies show that IgG specific for unfolded/sequential Bet v 1 epitopes is not inhibited by folded Bet v 1 and hence the latter seem to represent cryptic epitopes. IgG reactivity to Bet v 1 peptides did not correlate with IgG reactivity to the corresponding Mal d 1 peptides and therefore does not seem to be a result of primary sensitization to PR10 allergen‐containing food. Natural Bet v 1‐specific IgG antibodies inhibited IgE binding to Bet v 1 only poorly and could even enhance Bet v 1‐specific basophil activation.Conclusion: IgE and IgG antibodies from BPA patients and birch pollen‐exposed non‐sensitized subjects recognize different epitopes. These findings explain why natural allergen‐specific IgG do not protect against allergic symptoms and suggest that allergen‐specific IgE and IgG have different clonal origin.

14 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NSNadezhda N. Shershakova
Nadezhda N. Shershakova
EBElena Bashkatova
Elena Bashkatova
ABAlexander Babakhin
Alexander Babakhin
SASergey M Andreev
Sergey M Andreev
ANAlexandra Nikonova
Alexandra Nikonova
MKMusa Khaitov
Musa Khaitov
Atopic dermatitis (AD) is a widespread and difficult to treat allergic skin disease and is a tough challenge for healthcare. In this study, we investigated whether allergen-specific immunotherapy (ASIT) with a monomeric allergoid obtained by succinylation of ovalbumin (sOVA) is effective in a mouse model of atopic dermatitis. An experimental model of AD was reproduced by epicutaneous sensitization with ovalbumin (OVA). ASIT was performed with subcutaneous (SC) administration of increasing doses of OVA or sOVA. The levels of anti-OVA antibodies, as well as cytokines, were detected by ELISA. Skin samples from patch areas were taken for histologic examination. ASIT with either OVA or sOVA resulted in a reduction of both the anti-OVA IgE level and the IgG1/IgG2a ratio. Moreover, ASIT with sOVA increased the IFN-γ level in supernatants after splenocyte stimulation with OVA. Histologic analysis of skin samples from the sites of allergen application showed that ASIT improved the histologic picture by decreasing allergic inflammation in comparison with untreated mice. These data suggest that ASIT with a succinylated allergen represents promising approach for the treatment of AD.

30 May 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
OEOlga Elisyutina
Olga Elisyutina
EFElena Fedenko
Elena Fedenko
RCRaffaela A. Campana
Raffaela A. Campana
ALAlla Litovkina
Alla Litovkina
NINataliya Ilina
Nataliya Ilina
MKMusa Khaitov
Musa Khaitov